Enveric Biosciences (ENVB) Current Taxes (2015 - 2024)
Enveric Biosciences (ENVB) posted Current Taxes of $261100.0 for Q4 2024, up 1069.91% sequentially from $22318.0 in Q4 2023, and up 1069.91% YoY from $22318.0 in Q1 2024.
Enveric Biosciences (ENVB) Current Taxes (2015 - 2024) Analysis & Trends
Enveric Biosciences has reported Current Taxes for 3 years, with the latest figure at $261100.0 in Q4 2024.
- Quarterly Current Taxes rose 1069.91% year-over-year to $261100.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $261100.0 (up 1069.91% YoY) and the FY2024 annual result came in at $261100.0, up 1069.91% from the prior year.
- Current Taxes rose to $261100.0 in Q4 2024 per ENVB's latest filing, from $22318.0 in the prior quarter.
- Over five years, Current Taxes peaked at $261100.0 in Q4 2024 and troughed at $6299.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 49.00 Mn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 76.32 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 76.36 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 261,100.00 |
| Dec 31, 2023 | 22,318.00 |
| Sep 30, 2023 | 9,449.00 |
| Jun 30, 2023 | 6,299.00 |
| Mar 31, 2023 | 217,326.00 |
| Sep 30, 2015 | 320,247.00 |
| Jun 30, 2015 | 448,707.00 |
| Mar 31, 2015 | 405,218.00 |